Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.

Sussell JA, Sheinson D, Wu N, Shah-Manek B, Seetasith A.

Adv Ther. 2020 Mar 14. doi: 10.1007/s12325-020-01283-4. [Epub ahead of print]

PMID:
32172510
2.

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder.

Seetasith A, Greene M, Hartry A, Burudpakdee C.

Clinicoecon Outcomes Res. 2019 Dec 4;11:741-755. doi: 10.2147/CEOR.S220007. eCollection 2019.

3.

Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US.

Kalilani L, Faught E, Kim H, Burudpakdee C, Seetasith A, Laranjo S, Friesen D, Haeffs K, Kiri V, Thurman DJ.

Neurology. 2019 May 7;92(19):e2197-e2208. doi: 10.1212/WNL.0000000000007448. Epub 2019 Apr 10.

4.

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

Seetasith A, Wong W, Tse J, Burudpakdee C.

J Med Econ. 2019 May;22(5):414-420. doi: 10.1080/13696998.2019.1580200. Epub 2019 Mar 1.

PMID:
30729850
5.

Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers.

Greene M, Burudpakdee C, Seetasith A, Behling M, Krasa H.

Curr Med Res Opin. 2019 Jan;35(1):97-103. doi: 10.1080/03007995.2018.1536651. Epub 2018 Nov 5.

PMID:
30322282
6.

Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data.

Wolf DC, Jaganathan S, Burudpakdee C, Seetasith A, Low R, Lee E, Gucky J, Yassine M, Schwartz DA.

Patient Prefer Adherence. 2018 May 21;12:869-878. doi: 10.2147/PPA.S148777. eCollection 2018.

7.

Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.

Seetasith A, Greene M, Hartry A, Burudpakdee C.

J Med Econ. 2018 Sep;21(9):888-901. doi: 10.1080/13696998.2018.1484373. Epub 2018 Jun 19.

PMID:
29862860
8.

Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.

Burudpakdee C, Wong W, Seetasith A, Corvino FA, Yeh W, Gubens M.

Lung Cancer. 2018 May;119:103-111. doi: 10.1016/j.lungcan.2018.03.008. Epub 2018 Mar 9.

9.

A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA.

Do TP, Seetasith A, Belleli R, Schlienger RG, Corda S, Burudpakdee C, Streefkerk HJ, Behr S.

Am J Cardiovasc Drugs. 2018 Jun;18(3):205-211. doi: 10.1007/s40256-017-0256-x.

PMID:
29177815
10.

On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.

Seetasith A, Holdford D, Shah A, Patterson J.

Res Social Adm Pharm. 2017 Jul - Aug;13(4):778-788. doi: 10.1016/j.sapharm.2016.07.005. Epub 2016 Aug 3.

PMID:
27595426
11.

Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.

Burudpakdee C, Lin HM, Wang W, Seetasith A, Zhu Y, Bonthapally V, Carson KR.

J Med Econ. 2016 Oct;19(10):965-72. doi: 10.1080/13696998.2016.1187622. Epub 2016 May 26.

PMID:
27152635
12.

Comparison of Resource use and Health Care Costs in New Initiators of Long-Acting Injectable (Lai) and Oral Second Generation Antipsychotics.

Seetasith A, Burudpakdee C.

Value Health. 2014 Nov;17(7):A464. doi: 10.1016/j.jval.2014.08.1295. Epub 2014 Oct 26. No abstract available.

Supplemental Content

Loading ...
Support Center